GeneHealth - Your precision medicine

Breast Fibroadenoma

Disease Details

Family Health Simplified

Buy Membership

Description: Breast fibroadenoma is a benign (non-cancerous) tumor composed of glandular and fibrous breast tissue, commonly affecting young women.
Type: Breast fibroadenoma is a type of benign (non-cancerous) breast tumor. The type of genetic transmission is not well-defined, but a combination of genetic and hormonal factors is considered to contribute to its development. There is no clear pattern of inheritance.
Signs And Symptoms: Fibroadenomas are benign tumours of the breast, most often present in women in their 20s and 30s. Clinically, fibroadenomas are usually solid breast lumps that are:

Painless
Firm or rubbery
Mobile
Solitary-round with distinct, smooth bordersPeople who have a simple fibroadenoma likely do not have an increased risk of developing malignant (harmful) breast cancer compared to the general population. Complex fibroadenomas may increase the risk of breast cancer slightly.In the male breast, fibroepithelial tumors are very rare, and are mostly phyllodes tumors. Exceptionally rare case reports exist of fibroadenomas in the male breast; however, these cases may be associated with antiandrogen treatment.
Prognosis: Fibroadenomas are benign breast tumors that generally have an excellent prognosis. They do not increase the risk of breast cancer. Many fibroadenomas remain stable or may even shrink over time. Treatment is often not necessary unless the fibroadenoma is large, painful, or growing, in which case surgical removal may be considered. Regular monitoring through physical exams and imaging is typically recommended.
Onset: Fibroadenoma of the breast typically presents in young women, usually between the ages of 15 and 35. These benign tumors can develop at any age but are most commonly seen during a woman's reproductive years.
Prevalence: The prevalence of breast fibroadenoma, a common benign breast tumor, varies widely but is generally reported to occur in approximately 10% of women. It is most frequently seen in women between the ages of 15 and 35.
Epidemiology: Of all breast tissue samples taken, fibroadenomas comprise about 50%, and this rate rises to 75% for tissue sample in women under the age of 20 years. Fibroadenomas are more frequent among women in higher socioeconomic classes and darker-skinned people. Body mass index and the number of full-term pregnancies were found to have a negative correlation with the risk of fibroadenomas. There are no known genetic factors that influence the rate of fibroadenomas. The rate of occurrence of fibroadenomas in women has been reported in literature to range from 7% to 13%.
Intractability: Breast fibroadenoma is generally not considered intractable. It is a benign tumor commonly found in younger women and often managed with regular monitoring. Surgical removal is an option if the fibroadenoma is large, painful, or shows rapid growth, but many do not require any intervention. Hence, it is typically manageable and treatable.
Disease Severity: Breast fibroadenoma is generally considered a benign (non-cancerous) condition. It is typically not life-threatening and often does not require treatment unless it causes discomfort or concern. However, regular monitoring and medical checkups are recommended to track any changes in size or symptoms.
Healthcare Professionals: Disease Ontology ID - DOID:1618
Pathophysiology: Breast fibroadenoma is a benign (non-cancerous) breast tumor that commonly occurs in young women. It is characterized by the presence of both stromal (connective tissue) and epithelial (glandular tissue) components.

Pathophysiology:
Fibroadenomas arise from the breast lobules, where the glandular and stromal tissues proliferate excessively, forming a well-circumscribed, palpable mass. The exact etiology is not well understood, but hormonal factors, particularly estrogen, are believed to play a role in their development and growth. Fibroadenomas consist of a mix of stromal and epithelial tissue that usually appears as a firm, rubbery, and mobile mass upon physical examination. They typically do not cause pain and are often discovered incidentally during routine breast exams or imaging studies.

Concern regarding fibroadenomas generally stems from distinguishing them from malignant breast tumors and monitoring any changes in size or characteristics over time.
Carrier Status: Breast fibroadenoma is a benign (non-cancerous) tumor in the breast that is most commonly found in young women. It is characterized by a solid, smooth, and firm mass that moves easily within the breast tissue when palpated. Fibroadenomas are not typically associated with a genetic carrier status, as they do not result from inherited genetic mutations. Instead, their exact cause is unknown but is believed to be linked to reproductive hormones.
Mechanism: Breast fibroadenomas are benign (non-cancerous) tumors that typically affect women during their reproductive years.

### Mechanism:
Fibroadenomas consist of both stromal (connective tissue) and epithelial (glandular tissue) components. They arise due to hyperplasia (overgrowth) of these tissues within the breast lobules.

### Molecular Mechanisms:
1. **Hormonal Influence**: Estrogen is believed to play a significant role in the development of fibroadenomas, given their higher prevalence during the reproductive years and possible increase in size during pregnancy or with oral contraceptive use.
2. **Genetic Factors**: While largely not well-defined, some genetic factors may predispose individuals to fibroadenomas. Mutations in certain genes could potentially influence the proliferation of mammary gland cells.
3. **Growth Factors**: Various growth factors, such as epidermal growth factor (EGF) and insulin-like growth factors (IGFs), may contribute to the development and growth of fibroadenomas by promoting cell division and tissue growth in the breast.

Despite being benign, any new or growing breast mass should be evaluated to rule out malignancy.
Treatment: Fibroadenomas can be expected to shrink naturally, so most are simply monitored. Monitoring fibroadenomas involves regular check-ups to make sure that the breast mass is not growing and is not potentially cancerous. Check-ups involve physical examinations performed every 3–6 months and optional diagnostic imaging performed every 6–12 months for 1–2 years. Generally, surgery is only recommended if the fibroadenoma gets larger or causes increased symptoms. They are removed with a small margin of normal breast tissue if the preoperative clinical investigations are suggestive of the necessity of this procedure. A small amount of normal tissue must be removed in case the lesion turns out to be a phyllodes tumour on microscopic examination.Because needle biopsy is often a reliable diagnostic investigation, some doctors may decide not to operate to remove the lesion, and instead opt for clinical follow-up to observe the lesion over time using clinical examination and mammography to determine the rate of growth, if any, of the lesion. A growth rate of less than sixteen percent per month in women under fifty years of age, and a growth rate of less than thirteen percent per month in women over fifty years of age have been published as safe growth rates for continued non-operative treatment and clinical observation.Some fibroadenomas respond to treatment with ormeloxifene.Fibroadenomas have not been shown to recur following complete excision or transform into phyllodes tumours following partial or incomplete excision.
Compassionate Use Treatment: For breast fibroadenoma, there isn't a specific "compassionate use treatment" widely recognized since fibroadenomas are generally benign and often do not require aggressive treatments. However, for patients seeking non-surgical management, some off-label or experimental treatments might be considered:

1. **High-Intensity Focused Ultrasound (HIFU)**: This non-invasive treatment targets and destroys fibroadenoma tissue using focused ultrasound waves. It's experimental but has shown promise in clinical trials.

2. **Cryoablation**: This involves freezing the fibroadenoma tissue to destroy it. Though primarily used for certain cancers, it has been employed off-label to treat fibroadenomas with some success.

3. **Laser Ablation**: Utilizing laser energy to shrink or destroy fibroadenoma tissue can be less invasive compared to surgery. This remains in the experimental treatment realm.

4. **Radiofrequency Ablation (RFA)**: This technique uses radiofrequency energy to heat and destroy fibroadenoma tissue. It's another minimally invasive option currently under exploration.

These treatments should be considered in consultation with a healthcare provider, focusing on the individual's particular circumstances and the potential risks and benefits.
Lifestyle Recommendations: Lifestyle recommendations for managing breast fibroadenoma include:

1. **Regular Monitoring**: Schedule routine breast exams and follow-up imaging as advised by your healthcare provider to monitor any changes in the fibroadenoma.

2. **Healthy Diet**: Maintain a balanced diet rich in fruits, vegetables, whole grains, and lean proteins. Reducing intake of caffeine and high-fat foods may help alleviate breast tenderness for some women.

3. **Exercise**: Engage in regular physical activity. Exercise can help maintain a healthy weight and may improve overall breast health.

4. **Stress Reduction**: Practice stress-reducing techniques such as yoga, meditation, or deep-breathing exercises, as stress can affect hormonal balance and potentially influence breast tissue.

5. **Avoiding Hormonal Therapies**: Limit the use of hormone-based treatments such as birth control pills or hormone replacement therapy unless prescribed by your doctor for specific indications, as hormones can impact breast tissue.

6. **Proper Supportive Bras**: Wearing a well-fitted, supportive bra can reduce breast discomfort and provide better overall breast support.

7. **Limiting Alcohol and Smoking**: Reducing or eliminating alcohol consumption and avoiding smoking can improve overall health and potentially reduce breast tissue changes.

Consult your healthcare provider for personalized advice and any concerns about fibroadenoma management.
Medication: For breast fibroadenoma, there is no specific medication typically used to treat the condition, as it is a benign tumor of the breast. Management usually involves regular monitoring to track any changes in the fibroadenoma. In some cases, surgical removal may be considered if the fibroadenoma is large, painful, or has atypical features.
Repurposable Drugs: For breast fibroadenoma, which is a benign breast tumor, there are currently no widely recognized repurposable drugs specifically approved for treating this condition. Management typically involves monitoring for changes or surgical removal if necessary.
Metabolites: There is limited specific information available directly linking breast fibroadenoma with particular metabolites. However, general studies on breast tissue health and tumors may investigate broader metabolic profiles. Metabolites typically studied in relation to breast tumors include lipids, amino acids, and other small molecules involved in energy metabolism. Some research suggests differences in these metabolite levels between normal breast tissue and benign tumors like fibroadenomas. Specific studies would be needed to identify precise metabolites associated with breast fibroadenomas.

"NAN" seems to be unclear in this context. If you were referring to a specific aspect related to fibroadenoma (such as a term, acronym, or context), please provide more details for a precise answer.
Nutraceuticals: Currently, there is no conclusive evidence that nutraceuticals can treat or prevent breast fibroadenomas. Fibroadenomas are benign breast tumors often requiring monitoring or surgical removal depending on size, symptoms, or patient preference. Consulting a healthcare provider is essential for tailored advice and treatment options.
Peptides: For breast fibroadenoma, there is no standard treatment involving peptides or nanotechnology currently in widespread clinical use. Fibroadenomas are benign breast tumors often treated through observation or surgical excision if symptomatic or growing. Research is ongoing, but no specific peptides or nanotechnologies have been established as a primary treatment for this condition.